Part I: Angiogenesis in cancer -- Strategies to prolong the nonangiogenic dormant state of human cancer / George N. Naumov and Judah Folkman -- Vascular endothelial growth factor: basic biology and clinical implications / Napoleone Ferrara -- Angiogenesis in solid tumors / Rakesh K. Jain and Dan G. Duda -- Pathophysiologic role of VEGF in hematologic malignancies / Klaus Podar ... [et al.] -- Tumor microenvironment and angiogenesis / Cheryl H. Baker and Isaiah J. Fidler -- Part II: Targeting angiogenesis for cancer therapy -- Tyrosine kinase inhibitors of angiogenesis / Janessa J. Laskin and Alan B. Sandler -- Development of antiangiogenic monoclonal antibodies for cancer therapy / Zhenping Zhu and Daniel J. Hicklin -- Targeting fibroblast growth factor / fibroblast growth factor receptor system in angiogenesis / Marco Rusnati and Marco Presta -- Development of the VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and discovery of the next generation of angiogenesis targets / John S. Rudge ... [et al.] -- Proteinases and their inhibitors in angiogenesis / Yves A. DeClerck, Khalid Bajou, and Walter E. Laug -- Prostaglandins and COX-2: role in antiangiogenic therapy / Kristin Hennenfent, Daniel Morgensztern, and Ramaswamy Govindan -- Integrins, adhesion, and coadhesion inhibitors in angiogenesis / Abebe Akalu and Peter C. Brooks -- Conventional therapeutics with antiangiogenic activity / Christian Hafner, Thomas Vogt, and Albrecht Reichle -- Vascular disrupting agents / David J. Chaplin, Graeme J. Dougherty, and Dietmar W. Siemann -- Vascular and hematopoietic stem cells as targets for antiangiogenic therapy / Carlos Almeida Ramos, Hans-Georg Kopp, and Shahin Rafii -- Genetic strategies for targeting angiogenesis / Anita Tandle, Mijung Kwon, and Steven K. Libutti -- Identification of new targets using expression profiles / Thomas R. Burkard ... [et al.]. Part III: Translating angiogenesis inhibitors to the clinic -- Clinical trial design and regulatory issues / Ramzi N. Dagher and Richard Pazdur -- Surrogate markers for antiangiogenic cancer therapy / Darren W. Davis -- Noninvasive surrogates / Bruno Morgan and Mark A. Horsfield -- Pharmacodynamic markers in tissues / Darren W. Davis -- Blood-based biomarkers for VEGF inhibitors / Amado J. Zurita, Hua-Kang Wu, and John V. Heymach -- Part IV: Treatment of specific cancers with angiogenesis inhibitors -- Antiangiogenic therapy for colorectal cancer / Paulo M. Hoff and Everardo D. Saad -- Combined modality therapy of rectal cancer / Christopher G. Willett and Dan G. Duda -- Antiangiogenic therapy for breast cancer / Pablo M. Bedano ... [et al.] -- Antiangiogenic therapy for lung malignancies / David J. Stewart -- Antiangiogenic therapy for prostate cancer / Leslie K. Walker, Glenn Liu, and George Wilding -- Antiangiogenic therapy for hematologic malignancies / Karen W.L. Yee and Francis J. Giles -- Antiangiogenic therapy for gliomas / Heinrich Elinzano and Howard A. Fine -- Antiangiogenic therapy for Kaposi's sarcoma / Henry B. Koon, Liron Pantanowitz, and Bruce J. Dezube -- Antiangiogenic therapy for melanoma / Keith Dredge and Angus G. Dalgleish -- Sunitinib and renal cell carcinoma / Robert J. Motzer and Sakina Hoosen.
This resource is supported by the Institute of Museum and Library Services under the provisions of the Library Services and Technology Act as administered by State Library of Iowa.